Evaluating provider report of fidelity to contingency management in opioid treatment programs.

Drug Alcohol Depend

Institute for Public Health and Medicine, Center for Dissemination and Implementation Science, Northwestern University Feinberg School of Medicine, 633 N. St Clair, Chicago, IL 60611, USA.

Published: December 2024

Introduction: With growing adoption of contingency management (CM) in addiction treatment programs, ensuring intervention fidelity over time is essential for improving patient outcomes. Nonetheless, ensuring an intervention is delivered as intended can be time- and resource-intensive for organizations. Finding ways to monitor fidelity without unduly burdening health systems is critical.

Methods: This study evaluated the feasibility of using provider report to monitor CM fidelity compared to traditional observer ratings using the CM Competence Scale, leveraging data from 28 opioid treatment programs that participated in a hybrid implementation-effectiveness trial. Providers (n = 86) reported CM fidelity across 3143 sessions with observer ratings conducted for 72 of these sessions from 29 providers to assess concurrence of provider- and observer-ratings.

Results: Providers reported high fidelity for most CM practices, with high concordance with ratings from trained observers on practices that were easily observable/objective (e.g., discussing reinforcement earned in current and future session). In contrast, concordance between provider and observer ratings was lower for more nuanced practices (e.g., making connections between CM and the patients' broader treatment and recovery goals).

Conclusions: Overall, our findings suggest that while provider-report may effectively capture many aspects of CM delivery, discrepancies in fidelity reporting of specific CM practices warrant further investigation. Future research is needed to determine the optimal approaches for ensuring providers consistently deliver all CM elements with fidelity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drugalcdep.2024.112544DOI Listing

Publication Analysis

Top Keywords

treatment programs
12
observer ratings
12
provider report
8
fidelity
8
contingency management
8
opioid treatment
8
ensuring intervention
8
monitor fidelity
8
evaluating provider
4
report fidelity
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.

Background: In preparation for therapeutic trails involving patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), there is a need for valid, disease-specific caregiver-reported outcome (CRO) measures capable of tracking symptomatic burden in response to therapy over time. CROs are useful tools in clinical trials for individuals with AD, MCI, and dementia who are unable to self-report. In addition, CROs are accepted by the United States Food and Drug Administration to support regulatory claims.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Unlearn.AI, San Francisco, CA, USA.

Background: Pivotal Alzheimer's Disease (AD) trials typically require thousands of participants, resulting in long enrollment timelines and substantial costs. We leverage deep learning predictive models to create prognostic scores (forecasted control outcome) of trial participants and in combination with a linear statistical model to increase statistical power in randomized clinical trials (RCT). This is a straightforward extension of the traditional RCT analysis, allowing for ease of use in any clinical program.

View Article and Find Full Text PDF

Background: The goal of the TREAT-AD Center is to enable drug discovery by developing assays and providing tool compounds for novel and emerging targets. The role of microglia in neuroinflammation has been implicated in the pathogenesis of Alzheimer's disease (AD). Genome-wide association studies, whole genome sequencing, and gene-expression network analyses comparing normal to AD brain have identified risk and protective variants in genes essential to microglial function.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: The Mini-Mental State Examination (MMSE) is a common screening tool in Alzheimer's disease (AD) clinical trials. MMSE score inflation at inclusionary visits poses challenges by potentially amplifying placebo responses and complicating the detection of treatment effects. Despite these concerns, prior research (e.

View Article and Find Full Text PDF

Background: evoke and evoke+ are phase 3, randomized, placebo-controlled trials currently investigating the glucagon-like peptide-1 receptor agonist semaglutide as disease-modifying therapy (DMT) in persons with early Alzheimer's disease (AD). How the evoke and evoke+ trial populations compare with other phase 3 programs for DMTs in early AD has not been described.

Method: We compare the inclusion/exclusion criteria and baseline characteristics of the evoke/evoke+ trial populations with those of Clarity AD (lecanemab) and TRAILBLAZER-ALZ-2 (donanemab): two recent phase 3 trials assessing anti-amyloid monoclonal antibodies in persons with early AD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!